SAN FRANCISCO, June 11, 2019 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global Digital Therapeutics (DTx) company with connected devices, mobile software and large data solutions presented two studies reporting new real-world results at the American Diabetes Association's (ADA) 79th Scientific Sessions in San Francisco, California.
Yifat Hershcovitz PhD. performed the two studies with Sharon Dar and Eitan Feniger of DarioHealth. The studies provide additional insights on how the use of Dario's mobile applications, within a complete digital therapeutics solution, may promote behavioral modifications and enhanced individual engagement with diabetes management. The study demonstrates how this behavioral change may improve glycemic outcomes sustained for a long period of time.
The studies present a retrospective data evaluation reviewing hundreds of Type 2 Diabetes (T2D) active Dario mobile app users.
More specifically, they highlight the following results:
- T2D Users of a Digital Diabetes Management System Experienced an Increase of In-Range Glucose Levels Linked to App Engagement. For 4,917 T2D users measuring more than 15 times per month, the average of % in-range readings (70-140 mg/dL) was increased in correlation to app engagement (occurrences of tagging meals, carbs, physical activity). For 833 T2D highly engaged (≥7 times per week) population the ratio of % in-range readings was increased by 10% and sustained for 6 months.
- Reduction of Blood Glucose Average Under 140mg/dL in People with T2D Using a Digital Diabetes Management. For 1,248 Dario active users with T2D, measuring more than 2 times per day on average for 6 months in a row, reduction of their blood glucose average (BG avg) was observed within the 6-month period. Of that group, 31% (387 users) achieved BG avg of <140 mg/dL (eA1C<6.5) after 3 months, showing a 19% reduction on average from baseline. Subgroup analyses of 568 non-insulin users revealed that 40% (226 users) achieved a BG avg <140 mg/dL after 3 months and sustained it for 6 months.
Furthermore, the research team revaluated extended real-world data for analysis published originally in ADA 2018 titled 'Type 2 Diabetes Users of a Digital Diabetes Management System Experience a Shift from Greater than 180 mg/dL to Normal Glucose Levels with Sustainable Results' for 17,156 active users. The analysis combining 2017 and 2018 data which total in 38,838 T2D active users and more than 3 million measurements showing comparable results to the 11.3% increase in the ratio of normal blood glucose range readings (80-120 mg/dL) and 19.3% reduction in average high blood glucose events (180-400mg/dL).
Olivier Jarry, President and Chief Commercial Officer of DarioHealth, commented, "It is a great honor to present these studies at the ADA's Scientific Sessions. Leveraging a methodological approach, our researchers could demonstrate positive gains in outcomes. Based on the studies, we believe that better engagement clearly leads to better health and improved clinical outcomes. Such engagement stems from years of experience in developing and refining a unique user experience that is encouraging frequent and meaningful interaction with the mobile application."
Erez Raphael, Chief Executive Officer of DarioHealth, commented, "At DarioHealth, we are continuing the journey in setting the standards in the Digital Therapeutics industry to provide self-management excellence. These studies, involving large real-world populations, create further evidence of the benefits that our platform provides to our users. We are utilizing real-world data and redefining the way we think about chronic conditions management."
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading global Digital Therapeutics (DTx) company revolutionizing the way people manage their health across the chronic condition spectrum. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, we developed a novel approach that empowers individuals to adjust their lifestyle in a personalized way. Our Cross Functional Team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Already one of the highest rated Diabetes solutions, its user-centric approach is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company states that it believes that better engagement clearly leads to better health and improved clinical outcomes and that the studies create further evidence of the benefits that Dario's platform provides to its users, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
SOURCE DarioHealth Corp.